Janus Henderson Group PLC purchased a new stake in DBV Technologies S.A. (NASDAQ:DBVT) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,540,579 shares of the company’s stock, valued at approximately $90,724,000. Janus Henderson Group PLC owned 5.52% of DBV Technologies as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Point72 Asset Management L.P. acquired a new position in shares of DBV Technologies in the 1st quarter valued at $1,120,000. Bank of America Corp DE lifted its stake in shares of DBV Technologies by 86.3% in the 1st quarter. Bank of America Corp DE now owns 26,574 shares of the company’s stock valued at $936,000 after purchasing an additional 12,309 shares during the period. Morgan Stanley lifted its stake in shares of DBV Technologies by 89.9% in the 1st quarter. Morgan Stanley now owns 249,988 shares of the company’s stock valued at $8,805,000 after purchasing an additional 118,317 shares during the period. Marshall Wace North America L.P. acquired a new position in shares of DBV Technologies in the 1st quarter valued at $3,566,000. Finally, Jane Street Group LLC acquired a new position in shares of DBV Technologies in the 1st quarter valued at $853,000. 45.52% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was first posted by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/10/11/2540579-shares-in-dbv-technologies-s-a-dbvt-purchased-by-janus-henderson-group-plc.html.
DBVT has been the topic of a number of analyst reports. BidaskClub downgraded DBV Technologies from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Morgan Stanley reissued an “overweight” rating and issued a $72.00 price target (up previously from $70.00) on shares of DBV Technologies in a research note on Friday, October 6th. Zacks Investment Research downgraded DBV Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, August 31st. Jefferies Group LLC reissued a “buy” rating and issued a $51.00 price target on shares of DBV Technologies in a research note on Tuesday, September 12th. Finally, Deutsche Bank AG increased their price target on DBV Technologies from $46.00 to $56.00 in a research note on Sunday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $56.29.
Shares of DBV Technologies S.A. (NASDAQ:DBVT) opened at 47.79 on Wednesday. The firm’s market cap is $2.20 billion. The company’s 50-day moving average price is $44.08 and its 200 day moving average price is $38.76. DBV Technologies S.A. has a 52 week low of $31.87 and a 52 week high of $48.11.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.